Literature DB >> 22327231

Primary prevention of sudden cardiac death of the young athlete: the controversy about the screening electrocardiogram and its innovative artificial intelligence solution.

Anthony C Chang1.   

Abstract

The preparticipation screening for athlete participation in sports typically entails a comprehensive medical and family history and a complete physical examination. A 12-lead electrocardiogram (ECG) can increase the likelihood of detecting cardiac diagnoses such as hypertrophic cardiomyopathy, but this diagnostic test as part of the screening process has engendered considerable controversy. The pro position is supported by argument that international screening protocols support its use, positive diagnosis has multiple benefits, history and physical examination are inadequate, primary prevention is essential, and the cost effectiveness is justified. Although the aforementioned myriad of justifications for routine ECG screening of young athletes can be persuasive, several valid contentions oppose supporting such a policy, namely, that the sudden death incidence is very (too) low, the ECG screening will be too costly, the false-positive rate is too high, resources will be allocated away from other diseases, and manpower is insufficient for its execution. Clinicians, including pediatric cardiologists, have an understandable proclivity for avoiding this prodigious national endeavor. The controversy, however, should not be focused on whether an inexpensive, noninvasive test such as an ECG should be mandated but should instead be directed at just how these tests for young athletes can be performed in the clinical imbroglio of these disease states (with variable genetic penetrance and phenotypic expression) with concomitant fiscal accountability and logistical expediency in this era of economic restraint. This monumental endeavor in any city or region requires two crucial elements well known to business scholars: implementation and execution. The eventual solution for the screening ECG dilemma requires a truly innovative and systematic approach that will liberate us from inadequate conventional solutions. Artificial intelligence, specifically the process termed "machine learning" and "neural networking," involves complex algorithms that allow computers to improve the decision-making process based on repeated input of empirical data (e.g., databases and ECGs). These elements all can be improved with a national database, evidence-based medicine, and in the near future, innovation that entails a Kurzweilian artificial intelligence infrastructure with machine learning and neural networking that will construct the ultimate clinical decision-making algorithm.

Entities:  

Mesh:

Year:  2012        PMID: 22327231     DOI: 10.1007/s00246-012-0244-5

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  15 in total

Review 1.  Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.

Authors:  Domenico Corrado; Antonio Pelliccia; Hans Halvor Bjørnstad; Luc Vanhees; Alessandro Biffi; Mats Borjesson; Nicole Panhuyzen-Goedkoop; Asterios Deligiannis; Erik Solberg; Dorian Dugmore; Klaus P Mellwig; Deodato Assanelli; Pietro Delise; Frank van-Buuren; Aris Anastasakis; Hein Heidbuchel; Ellen Hoffmann; Robert Fagard; Silvia G Priori; Cristina Basso; Eloisa Arbustini; Carina Blomstrom-Lundqvist; William J McKenna; Gaetano Thiene
Journal:  Eur Heart J       Date:  2005-02-02       Impact factor: 29.983

2.  Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.

Authors:  Barry J Maron; Paul D Thompson; Michael J Ackerman; Gary Balady; Stuart Berger; David Cohen; Robert Dimeff; Pamela S Douglas; David W Glover; Adolph M Hutter; Michael D Krauss; Martin S Maron; Matthew J Mitten; William O Roberts; James C Puffer
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

3.  An electrocardiogram should not be included in routine preparticipation screening of young athletes.

Authors:  Bernard R Chaitman
Journal:  Circulation       Date:  2007-11-27       Impact factor: 29.690

4.  Electrocardiograms should be included in preparticipation screening of athletes.

Authors:  Robert J Myerburg; Victoria L Vetter
Journal:  Circulation       Date:  2007-11-27       Impact factor: 29.690

5.  Prospective screening of 5,615 high school athletes for risk of sudden cardiac death.

Authors:  C M Fuller; C M McNulty; D A Spring; K M Arger; S S Bruce; B E Chryssos; E M Drummer; F P Kelley; M J Newmark; G H Whipple
Journal:  Med Sci Sports Exerc       Date:  1997-09       Impact factor: 5.411

6.  Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program.

Authors:  Domenico Corrado; Cristina Basso; Andrea Pavei; Pierantonio Michieli; Maurizio Schiavon; Gaetano Thiene
Journal:  JAMA       Date:  2006-10-04       Impact factor: 56.272

Review 7.  Artificial intelligence in medical diagnosis.

Authors:  P Szolovits; R S Patil; W B Schwartz
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

8.  Cost-effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes.

Authors:  Matthew T Wheeler; Paul A Heidenreich; Victor F Froelicher; Mark A Hlatky; Euan A Ashley
Journal:  Ann Intern Med       Date:  2010-03-02       Impact factor: 25.391

Review 9.  Hypertrophic cardiomyopathy in childhood.

Authors:  Barry J Maron
Journal:  Pediatr Clin North Am       Date:  2004-10       Impact factor: 3.278

10.  Screening for hypertrophic cardiomyopathy in young athletes.

Authors:  D Corrado; C Basso; M Schiavon; G Thiene
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.